ICON plc (NASDAQ: ICLR) is a world-renowned, Ireland-based company specialized in providing outsourced development services to the pharmaceutical, biotechnology, and medical device industries. These industries heavily rely on ICON’s broad range of services to inspire advancements in healthcare and draw transformative medicinal solutions into the limelight. Since its inception in 1990, ICON has maintained its commitment to establishing innovative operational strategies, geared towards cost-effective drug development that can directly impact human health positively.
ICON commemorates a global footprint, having successfully established operations in 40 countries, and offering its services across 80 total locations. This widespread cultivation has projected ICON into the league of top-tier clinical research organisations (CROs) globally, with a customer base extending from small, indigenous companies to large, multinational corporations.
The extensive portfolio of services provided by ICON encompasses everything from pre-clinical through to post-market trials. This includes strategic product development, clinical trial management, biometric activities, pharmacovigilance, and medical imaging, among others. With advanced technologies, ICON helps to expedite the development timeline, as well as increase the quality of clinical trials.
Apart from increasing development efficiencies, ICON consistently strives for improvement in their therapeutic area specialization, particularly in areas such as oncology, cardiovascular diseases, central nervous system (CNS) disorders, and endocrine/metabolic diseases. This diverse expertise, coupled with the client-centric culture within ICON, facilitates a unique perspective towards each project, initiating a personalized approach for solving complex challenges.
Within the framework of operational excellence and deep expertise in regulatory compliance, ICON’s services are paramount to pharmaceutical and medical device companies seeking faster and safer routes to market. ICON’s commitment to compliance and high-quality standards has positioned it as a trusted partner for customers in sensitive and highly regulated industries.
Since its inception, ICON's vision has always been hinged on taking on the global health challenges of today and the future. With relentless passion and innovative services that inspire health transformations, ICON continues to play a pivotal role in accelerating the path for bringing new drugs and medical devices into the market, thereby fostering a healthier world.
As the healthcare industry continues to grapple with myriad complexities and challenges, ICON has proven an invaluable partner in driving and delivering solutions that are innovative, efficient, cost-effective and of the highest quality. The indispensable role ICON plays in drug development solidly places it at the forefront of contributing to the fundamental advances of global health.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Marram Investment Management exited its position in ICON Public Limited Company (ICLR) at breakeven due to a deteriorating moat and increasing competitive pressures in the clinical research organization industry. The firm noted that unhealthy industry dynamics and AI-driven cost efficiencies are leading to a lack of pricing power. Despite ICLR not being among the top popular stocks for hedge funds, Marram believes AI stocks offer greater upside potential.
Icon PLC (ICLR) saw its stock rise by 3.3% to $169.55, yet it remains undervalued according to GuruFocus's GF Value™ estimate, suggesting a potential 17.6% upside. The company boasts a strong GF Score™ of 95/100, driven by excellent profitability and growth, though its financial strength is moderate. However, investors should note the mixed sentiment from gurus and significant insider selling totaling $4.0M, indicating a cautious outlook from some.
ICON PLC director Eugene Pacelli McCague exercised 3,255 fully vested stock options at $125.74 per share and simultaneously sold the same number of ordinary shares at $175 per share on September 17, 2026. These transactions, detailed in a Form 4 filing, resulted in his direct beneficial ownership decreasing to 3,811 shares. The exercised options were granted in 2018 and are exempt from certain regulations due to ICON PLC's foreign private issuer status.
Icon PLC (ICLR) shares recently dropped 3.3%, but GuruFocus's GF Value™ suggests the stock is undervalued by 20.9% at $164.11, despite a high trailing P/E ratio. The company boasts a strong GF Score™ of 96/100, driven by excellent profitability and valuation scores, though insider selling activity and financial strength warrant caution. Investors are advised to consider these mixed signals before making investment decisions.
S&P 500 futures are rising in premarket trading, indicating a positive start for U.S. stock markets. Among individual stocks, OceanaGold Corp. (OGC) and Krystal Biotech Inc. (KRYS) saw notable gains of 4.6% each, while Xenon Pharmaceuticals and Icon PLC are reportedly lagging.